Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

A 65-year-old woman presents to her primary care provider with a chief complaint of "feeling winded" for the last 3 weeks.